| Q4 2022 |
3 |
$16.8M |
+$4.2M |
-$16.1M |
-$11.9M |
CRL, AZTA, FWONK
|
13F-HR |
2/14/2023, 12:47 PM |
| Q3 2022 |
3 |
$24.2M |
+$3.49M |
-$3.91M |
-$420K |
AZTA, CTLT, CRL
|
13F-HR |
11/14/2022, 08:48 AM |
| Q2 2022 |
3 |
$34.1M |
$0 |
-$15.9M |
-$15.9M |
CTLT, AZTA, CRL
|
13F-HR |
8/15/2022, 03:04 PM |
| Q1 2022 |
3 |
$57.4M |
$0 |
-$36.9M |
-$36.9M |
AZTA, CTLT, CRL
|
13F-HR |
5/16/2022, 08:58 AM |
| Q4 2021 |
3 |
$117M |
+$258K |
-$55.2M |
-$54.9M |
AZTA, CTLT, CRL
|
13F-HR |
2/14/2022, 12:43 PM |
| Q3 2021 |
5 |
$176M |
$0 |
-$24.2M |
-$24.2M |
AZTA, CTLT, CRL, BIO, CELL
|
13F-HR |
11/15/2021, 12:27 PM |
| Q2 2021 |
5 |
$192M |
+$898K |
-$36.5M |
-$35.6M |
AZTA, CRL, CTLT, BIO, CELL
|
13F-HR |
8/17/2021, 12:05 PM |
| Q1 2021 |
6 |
$205M |
+$29M |
-$44.3M |
-$15.3M |
AZTA, CRL, CTLT, BIO, CELL
|
13F-HR |
5/17/2021, 08:21 AM |
| Q4 2020 |
5 |
$205M |
+$18.9M |
-$43M |
-$24.2M |
AZTA, CRL, CTLT, BIO, BLFS
|
13F-HR |
3/5/2021, 01:12 PM |
| Q3 2020 |
5 |
$187M |
+$2.89M |
-$56.5M |
-$53.6M |
AZTA, CRL, BIO, CTLT, CYRX
|
13F-HR |
11/16/2020, 07:15 AM |
| Q2 2020 |
6 |
$207M |
+$84.2M |
-$64.8M |
+$19.3M |
AZTA, CRL, BIO, CTLT, BRKR
|
13F-HR |
8/10/2020, 08:22 AM |
| Q1 2020 |
3 |
$136M |
+$56.4M |
-$45.9M |
+$10.5M |
BIO, AZTA, CTLT
|
13F-HR |
6/4/2020, 11:18 AM |
| Q4 2019 |
3 |
$140M |
+$16.1M |
-$9.85M |
+$6.24M |
BIO, AZTA, OLLI
|
13F-HR |
2/12/2020, 10:21 AM |
| Q3 2019 |
3 |
$120M |
+$56.8M |
-$33.7M |
+$23.1M |
BIO, AZTA, OLLI
|
13F-HR |
11/14/2019, 11:39 AM |
| Q2 2019 |
2 |
$92.9M |
+$3.69M |
-$2.03M |
+$1.66M |
BIO, EA
|
13F-HR |
8/14/2019, 11:54 AM |
| Q1 2019 |
2 |
$90.1M |
+$32.5M |
-$11.2M |
+$21.3M |
BIO, EA
|
13F-HR |
5/13/2019, 11:46 AM |
| Q4 2018 |
1 |
$52.2M |
$0 |
$0 |
|
BIO
|
13F-HR |
2/13/2019, 05:11 PM |